MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen

References

• Robertson DW, Katzenellenbogen JA, Long DJ, Rorke EA, Katzenellenbogen BS. Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem 1982;16:1–13.
   Google Scholar
• Gelmann EP. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol 1997;24(1 Suppl 1):S1–65–S1–70.
   PubMedGoogle Scholar
• Spitz DR, Azzam EI, Li JJ, Gius D. Metabolic oxidation/reduction reactions and cellular responses to ionizing radiation: A unifying concept in stress response biology. Cancer Metastasis Rev 2004;23:311–22.
   PubMed Web of Science ®Google Scholar
• Kovacic P, Osuna JA, Jr. Mechanisms of anti-cancer agents: Emphasis on oxidative stress and electron transfer. Curr Pharm Des 2000;6:277–309.
   PubMed Web of Science ®Google Scholar
• Klaunig JE, Kamendulis LM, Hocevar BA. Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol 2010;38:96–109.
   PubMed Web of Science ®Google Scholar
• Ozben T. Oxidative stress and apoptosis: Impact on cancer therapy. J Pharm Sci 2007;96:2181–96.
   PubMed Web of Science ®Google Scholar
• Ferlini C, Scambia G, Marone M, Distefano M, Gaggini C, Ferrandina G, et al. Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br J Cancer 1999;79:257–63.
   PubMed Web of Science ®Google Scholar
• Kallio A, Zheng A, Dahllund J, Heiskanen KM, Harkonen P. Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis 2005;10:1395–410.
   PubMed Web of Science ®Google Scholar
• Pfanner N, Geissler A. Versatility of the mitochondrial protein import machinery. Nat Rev Mol Cell Biol 2001;2:339–49.
   PubMed Web of Science ®Google Scholar
• Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, Degoul F. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 2003;13:145–57.
   PubMedGoogle Scholar
• Park SY, Chang I, Kim JY, Kang SW, Park SH, Singh K, et al. Resistance of mitochondrial DNA-depleted cells against cell death: Role of mitochondrial superoxide dismutase. J Biol Chem 2004;279:7512–20.
   PubMed Web of Science ®Google Scholar
• Ambrosone CB, Ahn J, Singh KK, Rezaishiraz H, Furberg H, Sweeney C, et al. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res 2005;65:1105–11.
   PubMed Web of Science ®Google Scholar
• Bewick MA, Conlon MS, Lafrenie RM. Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer. Breast Cancer Res Treat 2008; 111:93–101.
   PubMed Web of Science ®Google Scholar
• Glynn SA, Boersma BJ, Howe TM, Edvardsen H, Geisler SB, Goodman JE, et al. A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide. Clin Cancer Res 2009;15: 4165–73.
   PubMed Web of Science ®Google Scholar
• Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, et al. Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Res Treat 2010;124:433–9.
   PubMed Web of Science ®Google Scholar
• Hou SM, Falt S, Angelini S, Yang K, Nyberg F, Lambert B, et al. The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis 2002;23:599–603.
   PubMed Web of Science ®Google Scholar
• Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, et al. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 2009;27:2163–9.
   PubMed Web of Science ®Google Scholar
• Pabalan N, Francisco-Pabalan O, Sung L, Jarjanazi H, Ozcelik H. Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer. Breast Cancer Res Treat 2010;124:531–41.
   PubMed Web of Science ®Google Scholar
• Bewick MA, Lafrenie RM, Conlon MS. Nucleotide excision repair polymorphisms and survival outcome for patients with metastatic breast cancer. J Cancer Res Clin Oncol 2011; 137:543–50.
   PubMed Web of Science ®Google Scholar
• Hartikainen JM, Kataja V, Pirskanen M, Arffman A, Ristonmaa U, Vahteristo P, et al. Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families. Clin Genet 2007;72:311–20.
   PubMed Web of Science ®Google Scholar
• Mitrunen K, Sillanpaa P, Kataja V, Eskelinen M, Kosma VM, Benhamou S, et al. Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. Carcinogenesis 2001;22:827–9.
   PubMed Web of Science ®Google Scholar
• Razandi M, Pedram A, Jordan VC, Fuqua S, Levin ER. Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer. Oncogene 2013;32: 3274–85.
   PubMed Web of Science ®Google Scholar
• Cho SK, Pedram A, Levin ER, Kwon YJ. Acid-degradable core-shell nanoparticles for reversed tamoxifen-resistance in breast cancer by silencing manganese superoxide dismutase (MnSOD). Biomaterials 2013;34:10228–37.
   PubMed Web of Science ®Google Scholar
• Wozniak K, Kolacinska A, Blasinska-Morawiec M, Morawiec-Bajda A, Morawiec Z, Zadrozny M, et al. The DNA-damaging potential of tamoxifen in breast cancer and normal cells. Arch Toxicol 2007;81:519–27.
   PubMed Web of Science ®Google Scholar
• Ray G, Husain SA. Oxidants, antioxidants and carcinogenesis. Indian J Exp Biol 2002;40:1213–32.
   PubMedGoogle Scholar
• Mandlekar S, Yu R, Tan TH, Kong AN. Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res 2000;60:5995–6000.
   PubMed Web of Science ®Google Scholar
• MacCallum J, Cummings J, Dixon JM, Miller WR. Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours. Br J Cancer 2000;82:1629–35.
   PubMed Web of Science ®Google Scholar